Equity Update: China Equities Surge on Stimulus

Equities 5 minutes to read

Eleanor Creagh

Australian Market Strategist, Saxo

Summary:  Today we mull the prospect of continued monetary and fiscal stimulus from China. As well as the prospect for downward revisions to growth and earnings which elevates tail risks, but is countered with ongoing policy support.


The S&P 500 and the Nasdaq on Friday closed at an all-time high, but although equities remain resilient, doubts remain about the impact of the virus outbreak on global growth and treasury yields edged lower. Across equities, investors are banking that ample global liquidity and supportive central banks will backstop equity prices even in the face of weaker economic growth. The prospect of weaker inflation via a weaker commodity complex, strong USD and disinflationary pressures arising impact of the coronavirus outbreak underpin an already ongoing recalibration of long term interest rate expectations. This is turn drives large amounts of capital up the risk spectrum into equity markets.

Asian stocks have started the week on a mixed footing, Chinese equities are in the green as investors are heeding the impending monetary and fiscal stimulus and influx of liquidity from the PBOC. Pledges from officials that vow to meet China’s 2020 growth targets underscores the sentiment that authorities will prioritise short term growth over financial stability and deleveraging goals. With this in mind markets expect enough policy support to mitigate downside risks and mainland equities have now recovered all of the losses seen following the Lunar New Year holidays.

In line with those expectations to support the economy, the PBOC today cut interest rates on its one year medium-term lending facility (MLF) by 10 basis points to 3.15% in a bid to reduce funding costs. This along with offering 200 billion yuan of one-year medium-term loans. The move all but guarantees a similar reduction in the loan prime rate (LPR – the new benchmark loan rate) come Feb 20. The pledges of additional fiscal stimulus that came over the weekend, in the form of corporate tax cuts are also lending support to mainland equities today and fuelling risk sentiment.

Continued policy support, both fiscal and monetary, will be required in China to mitigate downside risks from the coronavirus outbreak and promote a self-sustaining trajectory for growth. On that basis we expect more RRR cuts, along with further cuts in the MLF/LPR and more support for private firms as this sector continues to drive job creation, accounting for 80% of jobs and more than 90% of new jobs, according to the National Development and Reform Commission of the People's Republic of China. Limiting job losses is as ever a key focus as employment remains key for social stability.

Elsewhere in Asia a big miss on Japan 4Q GDP (-6.3% vs. -3.8% estimate) is souring sentiment in Japanese equities. Although the buoyant sentiment across mainland markets has softened the blow.

It is our sense that the Japan 4Q GDP data, which is pre virus outbreak, is just a taste of what is to come in terms of downside surprises to growth. The irony is that as we outlined above, in the current investment paradigm, this bad news is good news as investors anticipate more liquidity. Allowing equities to diverge further from economic fundamentals. Although 2019 saw multiple downwards revision to global growth and earnings forecasts, the S&P 500 returned 30% as the Fed and a raft of other central banks across the globe pivoted their policy stance early in the year. This served as a costly reminder for many not to fight liquidity. As the PBOC pledge ongoing support for the Chinese economy and fiscal stimulus efforts are ramped up, investors do not want to make the same mistake in 2020.

The caveat – fat tails! As we discussed on Friday, there are still many unknowns as it relates to the ultimate impact of the coronavirus outbreak. There is a huge question mark over the reliability of all data relating to COVID-19 cases. This means that within any forecast outcomes should be embedded an enormous degree of variability. As is often case, garbage in, garbage out - incorrect or poor-quality input will produce faulty output, which is likely the case here given the lack of reliable data. And the current virus outbreak may represent an example of a devastating real world event for which a normally distributed model will understate various outcomes potentially leading to large mispricing of risk. Given the complete lack of reliable data we must balance complacent markets with elevated tail risks, participating in the upside momentum and maintaining optionality/tail risk hedging with respect to potentially much more negative outcomes.

Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-sg/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Markets or its affiliates.

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.